Obizur
Obizur (factor VIII) is a clotting factor replacement that's infused through the veins to treat bleeding episodes in adults with an autoimmune blood condition called acquired hemophilia A. It's typically given at a hospital that's designated as a hemophilia treatment center. How long your treatment is depends on things like your health status and how serious your bleed is. Obizur (factor VIII) doesn't treat the inherited form of this blood condition (congenital hemophilia A) like other similar medications do. Obizur (factor VIII) doesn't have many known side effects.
What is Obizur (factor VIII)?
What is Obizur (factor VIII) used for?
- Bleeding in adults with acquired hemophilia A (AHA)
How Obizur (factor VIII) works
Obizur (factor VIII) is a coagulation (clotting) factor replacement for adults with acquired hemophilia A who have problems with their clotting factor VIII (FVIII). Clotting factors are proteins in the blood that help control bleeding.
Obizur (factor VIII) works by temporarily replacing factor FVIII in the blood. As a result, the medication helps control bleeds in people who have low levels of functioning factor VIII that's naturally found in the blood.
Drug facts
| Common Brands | Obizur |
|---|---|
| Drug Class | Coagulation factor replacement |
| Controlled Substance Classification | Not a controlled medication |
| Generic Status | No lower-cost generic available |
| Availability | Prescription only |
Side effects of Obizur (factor VIII)
The following side effects may get better over time as your body gets used to the medication. Let your healthcare provider know immediately if you continue to experience these symptoms or if they worsen over time.
Common Side Effects
See Risks and Warnings.
Obizur (factor VIII) serious side effects
Contact your healthcare provider immediately if you experience any of the following.
- Allergic reaction: swelling underneath the skin around the eyes, mouth, or throat (angioedema); hives; chest tightness; shortness of breath; wheezing; low blood pressure
The following Obizur (factor VIII) side effects have also been reported
Side effects that you should report to your care team as soon as possible:
- Allergic reactions or angioedema—skin rash, itching or hives, swelling of the face, eyes, lips, tongue, arms, or legs, trouble swallowing or breathing
Pros and cons of Obizur (factor VIII)
Pros
- Works well to treat bleeding episodes in adults with acquired hemophilia A
- Only medication that directly replaces FVIII approved for the treatment of bleeding in AHA
- Few known side effects
- Provider can tailor additional doses based on your response to treatment and your FVIII levels (no "one-size-fits-all")
Cons
- Can't give to yourself at home
- Can't use to prevent bleeding episodes from happening (can only treat current bleeding episodes)
- Not for people with allergy to hamsters; can cause allergic reactions since it's lab-made using genetically-engineered hamster cells
- Unknown if safe during pregnancy or while breastfeeding
Pharmacist tips for Obizur (factor VIII)
- During treatment, your provider will check that your bleeding is improving. Your provider will also check your blood work to make sure that Obizur (factor VIII) is helping to bring your factor VIII levels back to normal.
- Let your provider know right away if you have any problems or allergic reactions after your Obizur (factor VIII) infusion. These reactions can include chest tightness, trouble breathing, wheezing, itchy skin, hives, or lightheadedness. Your provider will probably need to stop the infusion and treat your symptoms right away.
Risks and warnings for Obizur (factor VIII)
Obizur (factor VIII) can cause some serious health issues. This risk may be even higher for certain groups. If this worries you, talk to your doctor or pharmacist about other options.
Allergic reaction
- Risk factors: Hamster allergy
Rarely, Obizur (factor VIII) can cause allergic reactions, which can be serious. Sometimes, these reactions can lead to life-threatening situations like anaphylaxis, which can include the closing of the throat. Get medical help right away if you experience chest tightness, shortness of breath, wheezing, swelling, or rash.
Development of antibodies
There's a chance that Obizur (factor VIII) can stop working well for you even though it worked well when you first started treatment. In a clinical study, nearly 1 out of 4 (26%) people who were treated with Obizur (factor VIII) developed inhibitory antibodies to the medication. These antibodies are proteins that can attach to the medication and make it work less well.
Your provider will keep track of how well Obizur (factor VIII) seems to be working for you during treatment. If you seem to stop responding to the medication, your provider might suspect that you've developed antibodies against the medication and might treat your bleeding another way.
Obizur (factor VIII) dosage
Typical dosage for Obizur (factor VIII)
This medication is given as an infusion through the veins (intravenously or IV). It must be given by a healthcare provider in a hospital or emergency care setting that's designated as a hemophilia treatment center.
Your provider will calculate your starting dose based on your body weight; the typical starting dose is 200 units/kg of weight.
Any following doses of Obizur (factor VIII) are given every 4 to 12 hours. How often the medication is given depends on how serious your bleed is, your response to the medication, and the FVIII levels in your blood (to make sure they're reaching a particular range that's safe for you).
Obizur (factor VIII) contraindications
Contraindications are specific health conditions or situations in which a person should not take a medication due to safety concerns. If you have any of the following conditions or if any of the following apply to you, let your healthcare provider know because Obizur (factor VIII) will not be safe for you to take.
- Allergies to hamsters
- Congenital hemophilia A with inhibitors
What are alternatives to Obizur (factor VIII)?
To treat active bleeds or to prevent bleeding episodes during surgery in people with the following conditions: